Search
01/01/2023
High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion
Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion. CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00518-6. PMID:36031661. IF:4.800(Q1/2D).
01/01/2023
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
Del Principe, MI, Seidel, D, Criscuolo, M, Dargenio, M, Racil, Z, Piedimonte, M, Marchesi, F, Nadali, G, Koehler, P, Fracchiolla, N, Cattaneo, C, Klimko, N, Spolzino, A, Karapinar, DY, Demiraslan, H, Duarte, RF, Demeter, J, Stanzani, M, Melillo, LMA, Basilico, CM, Cesaro, S, Paterno, G, Califano, C, Delia, M, Buzzatti, E, Busca, A, Cornely, OA, Pagano, L, Alakel, N, Arsenijevi'c, VA, Camus, V, Falces-Romero, I, Itzhak, L, Kouba, M, Martino, R, Sedlacek, P, Weinbergerova, B. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope. MYCOSES. 2023; 66(1)DOI:10.1111/myc.13524. PMID:36064299. IF:4.100(Q1/2D).
01/01/2023
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
Barba, P, Morgades, M, Montesinos, P, Gonzalez-Campos, J, Torrent, A, Gil, C, Bernal, T, Tormo, M, Mercadal, S, Novoa, S, Garcia-Cadenas, I, de Llano, MPQ, Cervera, M, Coll, R, Bermudez, A, Amigo, ML, Monsalvo, S, Esteve, J, Garcia-Boyero, R, Novo, A, Rivas, JMH, Cladera, A, Martinez-Sanchez, P, Serrano, J, Artola, MT, Soria, B, Abella, E, Vall-Llovera, F, Bergua, J, Herrera, P, Barrios, D, Ribera, JM. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols. Hemasphere. 2023; 7(1)DOI:10.1097/HS9.0000000000000810. PMID:36583094. IF:11.900(Q1/1D).
01/01/2023
High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion (vol 30, pg 51, 2023)
Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion (vol 30, pg 51, 2023). CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00564-0. PMID:36460806. IF:4.800(Q1/2D).
01/01/2023
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
Cruz D., Rodríguez-Romanos R., González-Bartulos M., García-Cadenas I., de la Cámara R., Heras I., Buño I., Santos N., Lloveras N., Velarde P., Tuset E., Martínez C., González M., Sanz G.F., Ferrá C., Sampol A., Coll R., Pérez-Simón J.A., López-Jiménez J., Jurado M., Gallardo D.. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1066393. PMID:36742309. IF:5.700(Q1/3D).
01/01/2023
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Kwon M., Iacoboni G., Reguera J.L., López Corral L., Morales R.H., Ortiz-Maldonado V., Guerreiro M., Caballero A.C., Domínguez M.L.G., Pina J.M.S., Mussetti A., Sancho J.M., Bastos-Oreiro M., Catala E., Delgado J., Henriquez H.L., Sanz J., Calbacho M., Bailén R., Carpio C., Ribera J.M., Sureda A., Briones J., Hernandez-Boluda J.C., Cebrián N.M., Martin J.L.D., Martín A., Barba P.. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. HAEMATOLOGICA. 2023; 108(1)DOI:10.3324/haematol.2022.280805. PMID:35770532. IF:10.100(Q1/2D).
01/01/2023
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Dickinson M.J., Barba P., Jäger U., Shah N.N., Blaise D., Briones J., Shune L., Boissel N., Bondanza A., Mariconti L., Marchal A.-L., Quinn D.S., Yang J., Price A., Sohoni A., Treanor L.M., Orlando E.J., Mataraza J., Davis J., Lu D., Zhu X., Engels B., Moutouh-de Parseval L., Brogdon J.L., Moschetta M., Flinn I.W.. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discovery. 2023; 13(9)DOI:10.1158/2159-8290.CD-22-1276. PMID:37249512. IF:30.600(Q1/1D).
01/01/2023
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study
Solano C., Castro-Rebollo P., Pérez-Martínez A., López-Corral L., Barba-Suñol P., Kwon M., Ortiz V., Sanz-Caballer J., Caballero A.C., Martínez J., Cedillo Á., Sureda A.. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study. BMJ Open. 2023; 13(7)DOI:10.1136/bmjopen-2022-071371. PMID:37491085. IF:2.400(Q1/3D).